LivaNova PLC
$ 67.12
3.25%
17 Apr - close price
- Market Cap 3,555,389,000 USD
- Current Price $ 67.12
- High / Low $ 68.04 / 65.98
- Stock P/E N/A
- Book Value 21.96
- EPS -4.45
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE -0.19 %
- 52 Week High 71.92
- 52 Week Low 34.24
About
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$79.18
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-07-26 | 2023-05-03 |
| Reported EPS | 0.86 | 1.11 | 1.05 | 0.88 | 0.81 | 0.9 | 0.93 | 0.73 | 0.87 | 0.73 | 0.78 | 0.43 |
| Estimated EPS | 0.8104 | 0.92 | 0.868 | 0.49 | 0.8006 | 0.72 | 0.78 | 0.49 | 0.77 | 0.64 | 0.54 | 0.39 |
| Surprise | 0.0496 | 0.19 | 0.182 | 0.39 | 0.0094 | 0.18 | 0.15 | 0.24 | 0.1 | 0.09 | 0.24 | 0.04 |
| Surprise Percentage | 6.1204% | 20.6522% | 20.9677% | 79.5918% | 1.1741% | 25% | 19.2308% | 48.9796% | 12.987% | 14.0625% | 44.4444% | 10.2564% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.72 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIVN
2026-04-14 06:10:27
Tudor Investment Corp ET AL has acquired a new position of 33,332 shares in LivaNova PLC, valued at approximately $1.746 million, making institution investors collectively own 97.64% of the stock. LivaNova recently exceeded quarterly expectations with an EPS of $0.86 and revenue of $360.9 million, forecasting a FY2026 EPS of 4.15–4.25. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $74.78.
2026-04-11 05:34:00
This article from Stock Traders Daily provides an AI-generated analysis of Livanova Plc (NASDAQ: LIVN), indicating a neutral near- and mid-term outlook that could moderate a long-term positive bias. It highlights a significant 32.7:1 risk-reward setup, targeting a 9.5% gain against a 0.3% risk, and presents specific institutional trading strategies across different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging.
2026-04-06 07:10:53
Allspring Global Investments Holdings LLC reduced its stake in LivaNova PLC (LIVN) by 8.9% in Q4 2026, selling 19,629 shares and now owning 201,832 shares valued at $12.42 million. Despite this reduction, other institutional investors have increased their holdings, and LivaNova reported strong Q4 earnings, beating expectations with $0.86 EPS and revenue of $360.92 million. The stock holds a "Moderate Buy" consensus rating with an average price target of $74.78.
2026-04-04 07:39:11
Exchange Traded Concepts LLC recently acquired 15,768 shares of LivaNova PLC, valued at approximately $970,000, during the fourth quarter. This acquisition is part of a trend where institutional investors now own 97.64% of the company's stock. LivaNova PLC exceeded its Q4 earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $74.78.
2026-03-31 04:26:00
Livanova Plc (NASDAQ: LIVN) shows weak near-term sentiment while maintaining long-term strength, with no clear price positioning identified and elevated downside risk. Algorithmic models provide three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. Multi-timeframe analysis reveals divergent sentiment, suggesting choppy conditions with weak near-term and strong long-term signals.
2026-03-29 11:31:19
Tudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.
